


CCT Respiratory Support Guidelines

Purpose and Guideline Statement

To provide a clinical practice guideline for the management and initiation of respiratory support devices in patients presenting with respiratory failure.

Background

Acute respiratory failure is broadly defined as the inability to provide sufficient gas exchange due to insufficient oxygenation (type I or hypoxemic respiratory failure) or inability to clear carbon dioxide (type II or hypercapnic respiratory failure), or both. It is a common presenting condition treated in the emergency department with a high morbidity and mortality.



The management of acute respiratory failure often requires an escalation from various forms of non-invasive respiratory support devices to invasive ventilation. The type of respiratory support depends largely on the type of acute respiratory failure (although at times this is a mixed picture). The decision to escalate to invasive ventilation/intubation is largely based on clinical judgement and the patient's initial presentation and/or response to treatment.

Respiratory Support Guidelines

Hypoxemic respiratory failure covers a wide range of lung pathology. This guideline divides acute hypoxemic respiratory failure into the most common etiologies encountered in the Emergency Department, and provides initial options for respiratory support:



• Acute Respiratory Distress Syndrome: ARDS represents the most severe form of hypoxemic respiratory failure with a high mortality rate, and is due to diffuse inflammation of the lung parenchyma; the diagnosis of ARDS is based on the Berlin criteria (see below). In most cases, severe ARDS requires intubation, however mild ARDS (as classified by P/F ratio between 200-300) may be managed initially with non-invasive methods e.g. HFNC or NIPPV.

| | Acute Respiratory Distress Syndrome | | | | | | | |
|----------------------------|--|--|--|--|--|--|--|--|
| Timing | Within 1 week of a known clinical insult or new or worsening respiratory symptoms | | | | | | | |
| Chest imaging ^a | Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules | | | | | | | |
| Origin of edema | Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present | | | | | | | |
| Oxygenation ^b | | | | | | | | |
| Mild | 200 mm Hg < PaO_2/FiO_2 ≤ 300 mm Hg with PEEP or CPAP ≥5 cm H_2O^0 | | | | | | | |
| Moderate | 100 mm Hg < $PaO_2/FiO_2 \le 200$ mm Hg with PEEP ≥5 cm H_2O | | | | | | | |
| Severe | Pao ₂ /Fio ₂ ≤ 100 mm Hg with PEEP ≥5 cm H ₂ O | | | | | | | |

o Non-invasive ventilation: In the setting of mild ARDS as defined by the Berlin criteria, BiPAP or HFNC can be considered. It is important to note that trials of NIPPV should be limited to patients that can be closely monitored with intubation available as needed.

o Initial settings:

- Start at IPAP of 10/EPAP of 5.
- Higher PEEP/EPAP will allow for recruitment of alveoli and reduce shunt physiology.
- Lower driving pressure/pressure support will provide for lung protection

o COVID considerations:

- In the setting of COVID-19, initial management can include awake proning in addition to HFNC or NIPPV, however the patient should be closely monitored with intubation available as needed.
- <u>Pneumonia:</u> infection and subsequent interstitial edema creates a large area of dead space and shunt physiology.
 - o Non-invasive ventilation: HFNC reduces the work of breathing and allows for clearance of more secretions when compared to BiPAP, and may reduce mortality rates and days spent on mechanical ventilation. o Initial Settings:
 - Initiate and titrate flow rate against the patient's work of breathing in increments of 10 L/minute up to 60 L/minute, titrate FiO2 against oxygen saturation to target saturation.



• Congestive Heart Failure Exacerbation/Flash Pulmonary Edema: In the setting of acute flash pulmonary edema, respiratory failure occurs when excess interstitial and alveolar fluid prevents appropriate gas exchange by creating an area of dead space and shunt physiology.

o Non-invasive ventilation: For heart failure, CPAP is as effective as BiPAP; BiPAP may be used in patients with a mixed picture of hypoxemic and hypercapnic respiratory failure.

o Initial Settings: A high ePAP will maintain high intrathoracic pressures, reducing both preload and afterload, and reducing intrapulmonary shunting.

• Start at IPAP of 10/EPAP of 5

o Escalation is based on patient need, work of breathing, oxygenation and hemodynamics. Avoid exceeding pressures greater than 20 cmH20 to decrease aspiration risk.

Pulmonary embolism:

o Oxygen can decrease RV afterload. Patients with RV dysfunction/failure due to significant PE and who are hypoxemic should have oxygen applied, however management should be geared towards hemodynamics, clot management, and avoidance of positive pressure when possible as transition to positive pressure ventilation can lead to worsening RV dysfunction/failure.

Pneumothorax/Pleural effusion:

o Management: acute respiratory failure due to pleural effusion or tension pneumothorax may require pleural drainage.

Hypercapnic respiratory failure results from pump failure and can be divided into two general etiologies:

Asthma:

o Non-invasive ventilation: For asthma, driving pressure provides mechanical support for breathing and offloads the work of the respiratory muscles especially in the setting of fatigue. However, if driving pressure does not reduce respiratory effort, gas trapping can occur. Higher EPAP keeps the airway open during exhalation potentially offsetting Auto-PEEP.

o Initial Settings:

Start at IPAP of 10/EPAP of 5

o Escalation is based on patient need, work of breathing, oxygenation and hemodynamics. Avoid exceeding pressures greater than 20 cmH20 to decrease aspiration risk.



• <u>Chronic obstructive pulmonary disease:</u> acute bronchospasm in the setting of chronic emphysema/bronchitis results in significant muscle fatigue and respiratory acidosis, resulting in pump failure and subsequent hypercapnia

o Non-invasive ventilation: For COPD, the driving pressure (IPAP – EPAP) provides support during initiation of every breath o Initial Settings

- Start at IPAP of 10/EPAP of 5
- Titrate FiO2 to saturation 88-92%

o Escalation is based on patient need, work of breathing, oxygenation and hemodynamics. Avoid exceeding pressures greater than 20 cmH20 to decrease aspiration risk.


• <u>Acute and Acute on Chronic hypoventilation syndrome</u>: due to neuromuscular disease including but not limited to muscular dystrophy, and myasthenia gravis, or chest wall injury resulting in diaphragmatic weakness/paralysis; Chronic hypoventilation syndrome (e.g. obesity hypoventilation):

o Non-invasive ventilation: Similar to COPD/asthma, the key in acute hypoventilation syndrome is driving pressure, which provides mechanical support for each breath


- Start at IPAP of 10/EPAP of 5
- o Escalation is based on patient need, work of breathing, oxygenation and hemodynamics. Avoid exceeding pressures greater than 20 cmH20 to decrease aspiration risk.
- o High ePAP is required to overcome extra-thoracic pressures.

In general patients requiring High Flow Nasal Cannula, non-invasive and/or invasive mechanical ventilation should have respiratory therapy available for titration of therapies and ventilator settings.
















3. Fraction of Inspired Oxygen (Fio₂)

- If acceptable pulse oximetry waveform is present titrate down to lowest possible Fio₂ required for goal Oxygen Saturation (> 95%)
 - COPD, OSA/OHS: 88-92%
- If no lung pathology (ie intubated for airway protection) can do rapidly
- Otherwise ≈ ↓10% Q 10 minutes
- · Get ABG to confirm once at goal
- If you can't get Fio₂ less than 50%, see PEEP table below
 - Consider ARDS and other causes of Shunt Physiology and Severe Respiratory Failure

4. Positive End Expiratory Pressure

- Ensure patient is volume resuscitated and monitored
- Adjust PEEP per table to lowest Fio₂ and PEEP value to maintain adequate Spo₂
- · Monitor for appropriate response
 - If paradoxical response, ie Oxygen Saturation drops with higher PEEP or initiation of MV consider cardiac shunts and unilateral lung disease and shunt
 - · Chest xray and/or Lung US
 - · ECHO bubble study
 - Decrease PEEP and consider other treatments for hypoxemia
- If PEEP > 8 is needed consider ARDS and other causes of Shunt Physiology and Severe Respiratory Failure

| Fio ₂ | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 |
|------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|
| PEEP | 5 | 5 | 8 | 8 | 10 | 10 | 10 | 12 | 14 | 14 | 14 | 16 | 18 | 18-24 |

Cannot Oxygenate?

Cannot get Oxygen Saturation above acceptable goal?

or

 Need high Fio₂ (>50%) to maintain Oxygen Saturation?

Recruitment

- · Adjust PEEP according to Appendix 1
 - If oxygenation worsens stop, evaluate for cardiac or unilateral pulmonary shunt and consider other treatments
- Consider Higher PEEP strategy (Appendix 1)
- Consult RT or Intensivist for assistance with formal recruitment maneuver, APRV or other Open Lung Maneuvers

Does patient have ARDS?

- Acute onset of respiratory failure (< 1 week)
- B/L Chest Opacities/Pulmonary edema not fully explained by Cardiac Failure or Fluid Overload?
- P/F ratio ≤ 300 mm Hg on PEEP ≥ 5 cm H₂0

Follow ARDSnet LPVS strategy

- T_4-6 mL/kg IBW
- $P_{plat} \leq 30 \text{ mL H}_20$
- PEEP (See Appendix 1)
- Limit O₂

LPVS Failure?

- Spo₃<88 or Pao₃<55
- Fio₂ 100% and PEEP > 20 for 24 hours
- Fio₂ >70% and PEEP >15 for 72 hours

Position

- Place patient in reverse Trendelenburg
- Unilateral lung disease?
 - Good lung down (except massive hemoptysis/pulmonary hemorrhage)

Paralysis

- · Ensure adequate analgesia and sedation
- · Cisatracurium Besylate
 - 15 mg bolus
 - · 37.5 mg/hour infusion


Inhaled Pulmonary Vasodilators

- Nitric Oxide
- · Start at 5 ppm
- Titrate 1 ppm Q 30 min, max 20 ppm
- · Use lowest dose possible
- · Monitor Nitrogen Dioxide and Methemoglobin
- Epoprostenol
- Start at 20.000 ng/ml nebulized at 8ml/hour
- Titrate 10 ng/kg/min Q 30 min, max 50 ng.kg/min
- · Use lowest dose possible

Referral to ECMO Center for VV ECMO

- ·CESAR Trial Criteria
 - Severe but potentially reversible respiratory failure
- Murray Score > 3.0
- · ELSO Criteria







Algorithm for Ventilator Crisis Management **D**-Displacement · Look in mouth, listen to airway, breath sounds Ventilator Crisis? · Look at Vent Exhaled T_.≠ or < Prescribed T_.? Chest Xray to confirm correct position above carina if sure ETT is still below cords and cuff is functioning otherwise resecure airway **O**-Obstruction · Ensure patient isn't biting on the tube · Pass Suction Catheter · Lung US/Chest Xray to r/o Mucous Plug · Standard Suction if right lung · Unidirectional or Coude Suction if left · Consider Bronchoscopy Bronchodilators if from reactive airway disease P-Pneumothorax **D-Displacement** Examine for tracheal deviation, O-Obstruction asymmetrical chest expansion, decreased P-Pneumothorax, PEEP, Pain breath sounds E-Equipment Failure Lung US · Lung Point : Specific for PNTX · Lung Sliding: Presence rules out P-(auto) PEEP · Analyze expiratory flow waveform (see figure 1 above) · Disconnect patient from ventilator and apply manual BVM breaths P-Pain · Dysnchrony or Bucking Ventilator? · Ensure adequate analgesia and sedation Consult Respiratory Therapy (RT) to adjust MV parameters Consider temporary paralysis after adequate analgesia and sedation E-Equipment Malfunction · Disconnect patient from MV and apply manual BVM breaths Connect new MV · Consider different MV mode with RT



RESOURCES/REFERENCES

Behrendt, C. E. (2000). Acute Respiratory Failure in the United States. Chest, 118(4), 1100–1105. doi:10.1378/chest.118.4.1100

Pinsky, M. R., Summer, W. R., Wise, R. A., Permutt, S., & Bromberger-Barnea, B. (1983). Augmentation of cardiac function by elevation of intrathoracic pressure. *Journal of applied physiology: respiratory, environmental and exercise physiology, 54*(4), 950–955. https://doi.org/10.1152/jappl.1983.54.4.950

Bradley, T. D., Holloway, R. M., McLaughlin, P. R., Ross, B. L., Walters, J., & Liu, P. P. (1992). Cardiac output response to continuous positive airway pressure in congestive heart failure. *The American review of respiratory disease*, *145*(2 Pt 1), 377–382. https://doi.org/10.1164/ajrccm/145.2_Pt_1.377

Lin, M., Yang, Y. F., Chiang, H. T., Chang, M. S., Chiang, B. N., & Cheitlin, M. D. (1995). Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short-term results and long-term follow-up. *Chest*, 107(5), 1379–1386. https://doi.org/10.1378/chest.107.5.1379

Roberts CM, Brown JL, Reinhardt AK, et al. Non-invasive ventilation in chronic obstructive pulmonary disease: management of acute type 2 respiratory failure. *Clin Med (Lond)*. 2008;8(5):517-521. doi:10.7861/clinmedicine.8-5-517

Antonelli, M., Conti, G., Esquinas, A., Montini, L., Maggiore, S. M., Bello, G., ... Meduri, G. U. (2007). *A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome**. *Critical Care Medicine*, *35*(1), 18–25.doi:10.1097/01.ccm.0000251821.44259.f3

Wright, Brian. Lung-Protective Ventilation Strategies and Adjunctive Treatments for the Emergency Medicine Patient with Acute Respiratory Failure. *Emerg Med Clinic N Am.* (2014): 1-17.



APPENDIX

There are several devices available for non-invasive ventilation, detailed below:

High flow nasal cannula (HFNC):



Non-Invasive Positive Pressure Ventilation (NIPPV):



Effective Date: